Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 435-439

  Feitosa, Mary F ^a   An, Ping ^a   Ordovas, Jose M ^b   Ketkar, Shamika ^a   Hopkins, Paul N ^c   Straka, Robert J ^d   Arnett, Donna K ^e   Borecki, Ingrid B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Gene drug interaction; Increasing HDL C; Lipid responses to fenofibrate; Metabolic syndrome; Triglyceride lowering

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL 7ALPHA MONOOXYGENASE; COFACTOR 1; ENDOTHELIAL LIPASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; FATTY ACID BINDING PROTEIN 2; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RELATED RECEPTOR PROTEIN 1; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PDZ PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR PROTEIN; SCAVENGER RECEPTOR B; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; WD AND TETRATRICOPEPTIDE REPEATS 1;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; EFFECT SIZE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GROWTH CURVE; HEREDITY; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEINS A; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TRIGLYCERIDES;

EID: 79953030836     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.011     Document Type: Article

References (31)

1. Mathieu P., Pibarot P., Després J.P. Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manage 2006, 2:285-302.
2. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007, 67:121-153.
3. Steiner G. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. Cardiovasc Drugs Ther 2009, 23:403-408.
4. Scott R., O'Brien R., Fulcher G., et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
5. Barter P.J., Rye K.A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol 2008, 28:39-46.
6. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005, 54:1065-1074.
7. Lai C.Q., Arnett D.K., Corella D., et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 2007, 27:1417-1425.
8. Ruan X., Zheng F., Guan Y. PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 2008, 294:F1032-F1047.
9. Pollex R.L., Hegele R.A. Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med 2006, 3:482-489.
10. Dallongeville J., Cottel D., Wagner A., et al. The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides. BMC Med Genet 2008, 9:84.
11. Higgins M., Province M., Heiss G., et al. NHLBI Family Heart Study: objectives and design. Am J Epidemiol 1996, 143:1219-1228.
12. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
13. Smith J.A., Arnett D.K., Kelly R.J., et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet 2008, 16:603-613.
14. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995, 85:289-300.
15. Srivastava R.A., Jahagirdar R., Azhar S., Sharma S., Bisgaier C.L. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 2006, 285:35-50.
16. Talmud P.J., Hawe E., Martin S., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002, 11:3039-3046.
17. Liu Y., Ordovas J.M., Gao G., et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genomics 2009, 19:161-169.
18. Grallert H., Sedlmeier E.M., Huth C., et al. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 2007, 48:2614-2621.
19. Niculescu L.S., Fruchart-Najib J., Fruchart J.C., Sima A. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med 2007, 45:1133-1139.
20. Komurcu-Bayrak E., Onat A., Poda M., et al. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults. Clin Chem Lab Med 2008, 46:778-784.
21. Kisfali P., Mohás M., Maasz A., et al. Apolipoprotein A5 IVS3+476A allelic variant associates with increased triglyceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ J 2008, 72:40-43.
22. Hsu L.A., Ko Y.L., Chang C.J., Teng M.S., Wu S., Hu C.F. Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. Clin Chem Lab Med 2008, 46:1714-1719.
23. Yamada Y., Ichihara S., Kato K., et al. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. J Med Genet 2008, 45:22-28.
24. Huang X.S., Zhao S.P., Zhang Q., Bai L., Hu M. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. Atherosclerosis 2009, 204:e99-e102.
25. Cardona F., Guardiola M., Queipo-Ortuño M.I., Murri M., Ribalta J., Tinahones F.J. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis 2009, 206:148-152.
26. Irvin M.R., Kabagambe E.K., Tiwari H.K., et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet 2010, 3:462-467.
27. Christidis D.S., Liberopoulos E.N., Kakafika A.I., et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther 2006, 11:211-221.
28. Brisson D., Ledoux K., Bosse Y., et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002, 12:313-320.
29. Foucher C., Rattier S., Flavell D.M., et al. Response to micronized fenofibrate treatment is associated with the peroxisomeproliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 2004, 14:823-829.
30. Sima A., Iordan A., Stancu C. Apolipoprotein E polymorphism - a risk factor for metabolic syndrome. Clin Chem Lab Med 2007, 45:1149-1153.
31. Sertic J., Juricic L., Ljubic H., et al. Variants of ESR1, APOE LPL and IL-6 loci in young healthy subjects: association with lipid status and obesity. BMC Res Notes 2009, 2:203-207.